These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 29193928

  • 21. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Yarman S, Kurtulmus N, Bilge A.
    Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pituitary gland: can prolactinomas be cured medically?
    Molitch ME.
    Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
    [Abstract] [Full Text] [Related]

  • 27. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
    Shimon I.
    Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
    [Abstract] [Full Text] [Related]

  • 28. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO, Lu VM, Izzo A, De Biase G, Vilanilam G, Van Gompel JJ, Bernet V, Donaldson A, Olomu O, Meyer FB, Quinones-Hinojosa A, Chaichana KL.
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [Abstract] [Full Text] [Related]

  • 29. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.
    Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA.
    Clin Endocrinol (Oxf); 2000 Jan; 52(1):43-9. PubMed ID: 10651752
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Mean platelet volume in patients with prolactinoma.
    Tam AA, Kaya C, Başer H, Ersoy R, Çakır B.
    Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P, Eunson G, Bath L, Mulvihill A.
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Giant prolactinomas presenting as skull base tumors.
    Minniti G, Jaffrain-Rea ML, Santoro A, Esposito V, Ferrante L, Delfini R, Cantore G.
    Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
    [Abstract] [Full Text] [Related]

  • 37. Predictors of dopamine agonist resistance in prolactinoma patients.
    Vermeulen E, D'Haens J, Stadnik T, Unuane D, Barbe K, Van Velthoven V, Gläsker S.
    BMC Endocr Disord; 2020 May 19; 20(1):68. PubMed ID: 32429916
    [Abstract] [Full Text] [Related]

  • 38. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D.
    Neuroendocrinology; 2019 May 19; 109(1):42-50. PubMed ID: 30481756
    [Abstract] [Full Text] [Related]

  • 39. Dopamine receptor agonists for treating prolactinomas.
    Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G.
    Expert Opin Investig Drugs; 2002 Jun 19; 11(6):787-800. PubMed ID: 12036422
    [Abstract] [Full Text] [Related]

  • 40. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E.
    Endocrine; 2017 Jan 19; 55(1):223-230. PubMed ID: 27688009
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.